Stocks making the biggest moves in the premarket: Cloudera, Supernus Pharmaceuticals, FuboTV & more

Market Insider

Take a look at some of the biggest movers in the premarket:

Pfizer (PFE) – Pfizer and the government struck a deal for the drugmaker and partner BioNTech (BNTX) to provide 100 million more doses of its Covid-19 vaccine, increasing the total that Pfizer has agreed to provide to 200 million. The extra 100 million doses will be delivered by the end of July. Pfizer shares added 0.8% in premarket trading as of 7:32 a.m. ET.

Formula One (FWONA) – Formula One is in talks with Amazon.com (AMZN) to stream its Grand Prix auto races, according to a Financial Times interview with outgoing Formula One CEO Chase Carey.

FuboTV (FUBO) – FuboTV remains on watch, after chalking up its fifth straight double-digit percentage gain on Tuesday. The video streaming service’s stock has gone from $26.47 per share to $62 per share over that five-day stretch. The shares were down 9% in premarket trading as of 7:32 a.m. ET.

The RealReal (REAL) – The RealReal is also on watch after rising for six straight sessions and gaining nearly 41% over that time. On Tuesday, Baird Equity Research called the secondhand seller of luxury goods an “open-ended growth story.”

AstraZeneca (AZN) – The drugmaker said its Covid-19 vaccine should be effective against the new strain of coronavirus, according to an AstraZeneca spokesman in an email to Reuters.

Discovery Communications (DISCA) – Discovery has reportedly raised its stake in OWN, its joint venture with Oprah Winfrey, to 95% from 73%. Variety reports that Winfrey was paid more than $35 million in Discovery shares in reducing her stake to 5%.

Merck (MRK) – The drugmaker reached a deal with the U.S. government to manufacture and supply its Covid-19 therapeutic known as MK-7110. Late-stage trial results earlier this year showed the treatment reduced the risk of death or respiratory failure by 50%, and as well as a 60% likelihood of clinical improvement. The shares were slightly higher in premarket trading as of 7:32 a.m. ET.

Infosys (INFY) – The India-based information technology company signed a cloud partnership deal with Daimler, with the automaker seeking to innovate and transform its IT infrastructure.

Unilever (UL) – The consumer products giant expanded its partnership with the Burger King unit of Restaurant Brands (QSR), launching a meat-free Whopper in Latin America, the Caribbean and China.

Cloudera (CLDR) – The cloud software company struck an agreement for a $500 million term loan, and plans to use the money for general corporate purposes including stock buybacks. The shares gained 4% in premarket trading as of 7:32 a.m. ET.

Orasure Technologies (OSUR) – The Canadian maker of medical testing products and services said its saliva-based collection device was included in an Emergency Use Authorization granted by the Food and Drug Administration to 3B Black Biotech for its Covid-19 test. 3B Black Biotech is a maker of molecular diagnostic kits. The shares gained 7% in premarket trading as of 7:32 a.m. ET.

Magna International (MGA) – The Canada-based automotive supplier struck a joint venture deal with South Korea’s LG Electronics to build electric car components such as motors, inverters and on-board chargers.

Supernus Pharmaceuticals (SUPN) – The Rockville, Maryland-based drugmaker announced positive results from a phase 3 study of its experimental drug for attention deficit hyperactivity disorder. Supernus is already in the process of seeking approval for the drug for patients aged 6-17, and assuming a successful outcome, plans to submit a supplemental application to use the drug to treat adult ADHD. The shares gained 15% in premarket trading as of 7:32 a.m. ET.

Articles You May Like

S&P 500, Nasdaq-100 are getting an update. Trillions depend on who’s in and who’s out
Why Short Squeeze Stocks May Be 2025’s Hidden Gems
Warren Buffett’s Berkshire Hathaway scoops up Occidental and other stocks during sell-off
Are These AI Stocks Ready for a Comeback?
Nike just laid out an ambitious turnaround plan. But it will come at a cost.